Rose Capital Advisors LLC’s Ascendis Pharma A/S ASND Stock Holding History

Rose Capital Advisors LLC’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$823K	Buy	+3,087	New	+$721K	0.41%	45

Other funds holding ASND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Rose Capital Advisors LLC's ASND Position: Q2 2026 in Review

Rose Capital Advisors LLC opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 3,087 shares worth $823K. The stake represents 0.41% of the portfolio and ranks #45 among its holdings.

107 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Rose Capital Advisors LLC held 3,087 shares of Ascendis Pharma A/S worth $823K as of Q2 2026.
Ascendis Pharma A/S was a new Rose Capital Advisors LLC position in Q2 2026.
Ascendis Pharma A/S made up 0.41% of Rose Capital Advisors LLC's portfolio in Q2 2026, its #45 holding.
107 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Rose Capital Advisors LLC's 13F filing for Q2 2026, filed 7 Aug 2026.